Iron Deficiency Anemia Treatment Market Report 2026

Iron Deficiency Anemia Treatment Market Overview

• Iron Deficiency Anemia Treatment market size has reached to $8.83 billion in 2025 • Expected to grow to $16.17 billion in 2030 at a compound annual growth rate (CAGR) of 12.8% • Growth Driver: Rising Prevalence Of Chronic Kidney Disease Driving The Growth Of The Market Due To Increasing Diabetes Rates And Kidney Function Impairment • Market Trend: Next Generation Solutions In Iron Deficiency Anemia Treatment • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Iron Deficiency Anemia Treatment Market?

Iron deficiency anemia treatment refers to the medical strategies and interventions used to address and correct the deficiency of iron in the body. Iron deficiency anemia treatment utilizes iron supplements, dietary adjustments, or intravenous iron to replenish iron levels in the body, addressing the root cause of the deficiency and alleviating symptoms. The main types of iron deficiency anemia treatment include medications, blood transfusions, and others. Medications refer to drugs or substances used to treat, prevent, or manage diseases, including conditions including iron deficiency anemia. It offers various types of drugs, including ferrous sulfate, ferrous gluconate, ferrous fumarate, ferric hydroxide, sodium ferric gluconate, iron carbohydrates, and others for different therapy areas such as inflammatory bowel disease, renal, obstetrics and gynecology, congestive heart failure, oncology, and others. The various routes of administration include oral and injectable, and they are used by various end users such as hospitals, clinics, home care settings, and pharmacies.

What Is The Iron Deficiency Anemia Treatment Market Growth Forecast?

The iron deficiency anemia treatment market size is expected to see rapid growth in the next few years. It will grow to $16.17 billion in 2030 at a compound annual growth rate (CAGR) of 12.8%. The growth in the forecast period can be attributed to increasing geriatric population susceptibility, rising demand for rapid iron repletion therapies, expansion of injectable iron usage, growing focus on patient-centric treatment models, advancements in iron formulation technologies. Major trends in the forecast period include increasing adoption of intravenous iron therapies, rising use of high-bioavailability iron formulations, growing focus on personalized anemia treatment approaches, expansion of outpatient and home-based iron therapy, improved patient monitoring and compliance tools.

Global Iron Deficiency Anemia Treatment Market Segmentation

1) By Treatment Type: Medications, Blood Transfusions, Other Treatment Types 2) By Drug Type: Ferrous Sulfate, Iron Carbohydrates, Other Drug Types 3) By Therapy Areas: Inflammatory Bowel Disease, Oncology, Other Therapy Areas 4) By Route Of Administration: Oral, Injectable 5) By End User: Hospitals, Clinics, Home Care Settings, Pharmacies Subsegments: 1) By Medications: Oral Iron Supplements, Intravenous Iron Therapy, Iron-Based Injections, Erythropoiesis-Stimulating Agents 2) By Blood Transfusions: Packed Red Blood Cells Transfusion, Whole Blood Transfusion 3) By Other Treatment Types: Dietary Modifications, Iron Infusion Therapy, Long-Term Maintenance Iron Therapy

What Is The Driver Of The Iron Deficiency Anemia Treatment Market?

An increase in chronic kidney disease is expected to propel the growth of the iron deficiency anemia treatment market going forward. Chronic kidney disease (CKD) refers to the gradual loss of kidney function over time. The increase in chronic kidney disease (CKD) can be due to rising rates of diabetes, as prolonged high blood sugar levels damage the kidneys' blood vessels, impairing their ability to filter waste. Iron deficiency anemia treatment helps chronic kidney disease (CKD) to improve oxygen delivery to tissues, reduce fatigue, and enhance quality of life and can potentially improve kidney function by addressing the anemia that often results from reduced erythropoietin production in CKD. For instance, in April 2024, according to the report published by AstraZeneca, a UK-based pharmaceutical company, it is projected that by 2032, up to 16.5% of the population across eight countries, including the United States, Brazil, the United Kingdom, Spain, Germany, the Netherlands, China, and Australia, will be affected by chronic kidney disease (CKD), with a significant increase of up to 59.3% in advanced-stage cases. Therefore, an increase in chronic kidney disease is driving growth in the iron deficiency anemia treatment industry.

Key Players In The Global Iron Deficiency Anemia Treatment Market

Major companies operating in the iron deficiency anemia treatment market are Sanofi SA, Fresenius SE & Co. KGaA, Amgen Inc., Teva Pharmaceutical Industries Ltd., Sandoz Group AG, Daiichi Sankyo Company Limited, Lupin Limited, Zydus Lifesciences Limited, Alkem Laboratories Ltd., Pharmascience Inc., American Regent Inc., PharmaNutra S.p.A., Rockwell Medical Inc., Keryx Biopharmaceuticals Inc., Pharmacosmos A/S, AdvaCare Pharma USA LLC, Apotex Inc., Shield Therapeutics plc, CSL Vifor AG, Abbott Laboratories, Bayer AG, Pfizer Inc., Cipla Limited, Dr. Reddy’s Laboratories Ltd.

Global Iron Deficiency Anemia Treatment Market Trends and Insights

Major companies operating in the iron deficiency anemia treatment market are focusing on developing next-generation solutions, such as iron injections, to enhance treatment efficacy, safety, and patient convenience. Iron injection refers to a new or significantly improved injectable iron therapy that represents a major advancement in the treatment of iron deficiency or iron deficiency anemia. For instance, in March 2024, Cadila Pharmaceuticals, an India-based pharmaceutical company, launched Redshot FCM, an intravenous iron therapy using ferric carboxymaltose to treat iron deficiency anemia (IDA). It offers unique features, including advanced ferric carboxymaltose formulation for rapid iron replenishment, minimal anaphylaxis risk, high-dose single-infusion administration for swift correction, and pediatric applicability (1+ years) alongside adult use. It accelerates hemoglobin recovery and targets high-risk groups, including pregnant women and cancer patients, with superior tolerability.

What Are Latest Mergers And Acquisitions In The Iron Deficiency Anemia Treatment Market?

In March 2025, Hyloris Pharmaceuticals, a Belgium-based provider of specialty biopharmaceuticals, partnered with AFT Pharmaceuticals to co-develop HY‑094, a novel injectable therapy for iron deficiency and iron deficiency anemia (IDA). Through this collaboration, the companies aim to advance clinical development, manufacturing, and commercialization of HY‑094 across global markets, with Hyloris leading European operations and AFT focusing on markets outside Europe. This partnership highlights the IDA treatment market’s growing focus on innovative iron therapies and cross-border collaboration to improve patient access. AFT Pharmaceuticals is a New Zealand-based pharmaceutical company.

Regional Outlook

North America was the largest region in the iron deficiency anemia treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain

What Defines the Iron Deficiency Anemia Treatment Market?

The iron deficiency anemia treatment market consists of revenues earned by entities by providing services such as dietary counseling, monitoring and follow-up care, customized treatment plans, and management of side effects. The market value includes the value of related goods sold by the service provider or included within the service offering. The iron deficiency anemia treatment market also includes sales of iron-fortified foods, iron infusion kits, liquid iron supplements, and iron-rich multivitamins. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.